Thulium Laser Vaporesection Versus Transurethral Electrovaporization of the Prostate in High-Risk Patients with Benign Prostatic Hyperplasia
Zhu Z, Shen Z, Tu F, Zhu Y, Sun F, Shao Y, Wang H, Zhong S, Xu C. Photomed Laser Surg. 2012 Oct 31. [Epub ahead of print]

Source

1 Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai, China .

Abstract

Abstract Objective: The purpose of this study was to compare the safety and efficacy of the thulium laser vaporesection and transurethral electrovaporization of the prostate for the treatment of high-risk patients with benign prostatic hyperplasia. Background data: From September 2009 to March 2011, 98 consecutive patients with symptomatic bladder outlet obstruction caused by benign prostatic hyperplasia received either thulium laser vaporesection of the prostate (n=42) or transurethral electrovaporization of the prostate (n=56) at our institution. Materials and methods: Functional follow-up included measurement of International Prostate Symptom Score, quality of life score, maximal urinary flow rate, and post-voiding residual urine volume. All complications were recorded. Results: Thulium laser vaporesection of the prostate was slightly superior to transurethral electrovaporization of the prostate in catheterization time (2.1±0.9 vs. 4.5±1.3 days, p<0.0001) and postoperative hospital stay (4.4±1.8 vs. 6.6±2.0 days, p<0.0001). Within the observation period, both groups had a significant improvement from baseline in subjective or objective success rates; however, no significant difference was found between the two groups. Peri- and postoperative complications were fewer in the thulium laser group. Conclusions: Thulium laser vaporesection of the prostate is as effective as transurethral electrovaporization of the prostate in managing high-risk patients, with sufficient tissue ablation and acceptable hemostasis, and has the advantage of less morbidity and shorter catheter time and postoperative hospital stay.